Immunic Financials - Benzinga

Immunic Inc

IMUXNASDAQ

Trade with Public

Trade with Public

$15.40

-0.90-5.52%

At close: Aug 28, 5:00 PM EST

$16.23

0.835.42%

After Hours: Aug 28, 7:46 AM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Immunic Financials

Immunic (IMUX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Immunic Q2 EPS $(0.80) Beats $(1.10) Estimate

Immunic (NASDAQ:IMUX) reported quarterly losses of $(0.80) per share which beat the analyst consensus estimate of $(1.10) by 27.27 percent. This is a 60 percent increase over losses of $(2.00) per share from the same

Benzinga Newsdesk

Earnings Scheduled For May 13, 2026

Benzinga Insights

PRO
Immunic Q1 EPS $(1.08) Misses $(0.91) Estimate

Immunic (NASDAQ:IMUX) reported quarterly losses of $(1.08) per share which missed the analyst consensus estimate of $(0.91) by 18.68 percent. This is a 332 percent decrease over losses of $(0.25) per share from the same

Benzinga Newsdesk

PRO
Immunic Q4 EPS $(0.07) Beats $(0.09) Estimate

Immunic (NASDAQ:IMUX) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.09) by 18.6 percent. This is a 72 percent increase over losses of $(0.25) per share from the same

Benzinga Newsdesk

PRO
Immunic Q3 EPS $(0.13) Beats $(0.18) Estimate

Immunic (NASDAQ:IMUX) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.18) by 26.14 percent. This is a 45.83 percent increase over losses of $(0.24) per share from the same

Benzinga Newsdesk

PRO
Immunic Q2 EPS $(0.20) Misses $(0.17) Estimate

Immunic (NASDAQ:IMUX) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.17) by 15.61 percent. This is a 4.76 percent increase over losses of $(0.21) per share from the same

Benzinga Newsdesk